Condition
Recurrent Primary Peritoneal Carcinosarcoma
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Recruiting2
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06483048Phase 1Recruiting
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
NCT05920798Phase 1Recruiting
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT06393751Phase 1Withdrawn
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
Showing all 3 trials